Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Interferon alfa may interfere with the growth of tumor cells. Interleukin-2 may
stimulate a person's white blood cells to kill tumor cells. Drugs used in chemotherapy use
different ways to stop tumor cells from dividing so they stop growing or die. Combining
interferon alfa with interleukin-2 and fluorouracil may kill more tumor cells. It is not yet
known whether interferon alfa is more effective with or without interleukin-2 and
fluorouracil in treating metastatic kidney cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa combined
with interleukin-2 and fluorouracil to that of interferon alfa alone in treating patients who
have advanced metastatic kidney cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Medical Research Council
Collaborator:
European Organisation for Research and Treatment of Cancer - EORTC